Proteostasis Network Enhancement for CBS/PSP

📖 Wiki Page

therapeutic1061 wordssynced 2026-04-02

Proteostasis Network Enhancement for CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Proteostasis Network Enhancement for CBS/PSP</th>
</tr>
<tr>
<td class="label">Approach</td>
<td>UPS Enhancement</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Monomeric/oligomeric tau</td>
</tr>
<tr>
<td class="label">Clinical status</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Key drugs</td>
<td>Bortezomib</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Key Interactions</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>Immunosuppressants, antifungals</td>
</tr>
<tr>
<td class="label">Bortezomib</td>
<td>CYP3A4 substrates</td>
</tr>
<tr>
<td class="label">Trehalose</td>
<td>Limited drug interactions</td>
</tr>
<tr>
<td class="label">HDAC6 inhibitors</td>
<td>Limited data</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Ricolinostat</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">TUDCA</td>
<td>Phase 2</td>
</tr>
</table>

...

Proteostasis Network Enhancement for CBS/PSP

Overview

The proteostasis network is a critical defense mechanism that maintains cellular protein homeostasis by coordinating protein folding, quality control, and degradation. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), the proteostasis network becomes overwhelmed by pathological tau aggregation, leading to progressive neurodegeneration. This page discusses therapeutic strategies to enhance proteostasis network function and restore protein quality control in these tauopathies.

The Proteostasis Network in CBS/PSP

CBS and PSP are characterized by the accumulation of hyperphosphorylated tau protein into neurofibrillary tangles and astrocytic plaques. The proteostasis network normally handles protein synthesis, folding, and degradation, but in tauopathies, this system becomes dysfunctional:

Impaired protein degradation: Reduced activity of both the ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway
Chaperone dysfunction: Decreased expression and activity of heat shock proteins
Aggregate formation: Sequestration of functional proteins into insoluble aggregates
ER stress: Activation of the unfolded protein response (UPR)

Therapeutic Strategies

1. Ubiquitin-Proteasome System (UPS) Enhancement

The UPS is responsible for degrading most intracellular proteins, including phosphorylated tau. Enhancing UPS function can promote clearance of pathological tau species.

Proteasome Inhibitors

Bortezomib: A reversible proteasome inhibitor that can paradoxically enhance proteasome activity in neurons through feedback mechanisms. Used in combination with other agents.
Carfilzomib: An irreversible proteasome inhibitor with better blood-brain barrier penetration than bortezomib.

Mechanism

Proteasome enhancement works by:

Reducing tau phosphorylation through kinase modulation

Enhancing ubiquitin-conjugating enzyme activity

Promoting degradation of oligomeric tau species

Clinical Considerations

Monitor for peripheral neuropathy
Dose adjustment for renal impairment
Combination with autophagy inducers for synergistic effect

2. Autophagy-Lysosome Pathway Enhancement

The autophagy-lysosome pathway (ALP) is responsible for degrading aggregate-prone proteins and damaged organelles. Enhancing ALP function is a promising therapeutic strategy.

Pharmacological Inducers

mTOR Inhibitors

Rapamycin (Sirolimus): Allosteric mTOR inhibitor that induces autophagy. Studies show neuroprotective effects in tauopathy models [1].
Everolimus: Similar mechanism with better CNS penetration.

mTOR-Independent Inducers

Trehalose: Natural disaccharide that activates autophagy through mTOR-independent pathways [2]. Enhances clearance of tau aggregates in cellular and animal models.
Lithium: GSK-3β inhibitor with autophagy-activating properties.

TFEB Activation

Transcription factor EB (TFEB) is the master regulator of lysosomal biogenesis and autophagy. TFEB activators include:

Rapamycin: Promotes TFEB nuclear translocation
Small molecule TFEB activators: In development for CNS disorders
Protein phosphatase 2A (PP2A) activators: Enhance TFEB activity indirectly

3. Aggresome Targeting

Aggresomes are cytoplasmic inclusions that represent a cellular defense mechanism against toxic protein aggregates. While aggresome formation may be protective, targeting the aggresome machinery can enhance aggregate clearance.

HDAC6 Inhibitors

Histone deacetylase 6 (HDAC6) plays a crucial role in aggresome formation and autophagy. HDAC6 inhibitors include [3]:

Tubastatin A: Selective HDAC6 inhibitor
ACY-1215 (Ricolinostat): In clinical trials for various neurological conditions
Tubastatin A analogs: In development with improved CNS penetration

Mechanism

HDAC6 inhibition promotes:

Degradation of misfolded proteins through enhanced autophagy

Reduction in aggresome formation

Improved microtubule dynamics and intracellular transport

4. Combination Approaches

Combining UPS enhancement with autophagy induction may provide synergistic benefits, as these pathways are complementary:

5. Heat Shock Protein Modulators

Heat shock proteins (HSPs) are molecular chaperones that facilitate protein folding and prevent aggregation. Modulating HSP activity can enhance proteostasis.

HSP70 Inducers

Geldanamycin derivatives: 17-DMAG (Alvespimycin), 17-AAG (Tanespimycin)
Geldanamycin: HSP90 inhibitor that induces HSP70 expression
Small molecule HSP70 inducers: In development

Mechanism

HSP modulation works by:

Inducing HSP70 and HSP90 expression

Preventing tau aggregation

Promoting refolding of misfolded tau

Enhancing clearance of damaged proteins

Clinical Considerations

HSP90 inhibitors can cause hepatotoxicity
Careful monitoring required
May affect cardiac function

6. ERAD/UPR Enhancement

The endoplasmic reticulum-associated degradation (ERAD) pathway and unfolded protein response (UPR) are critical for managing ER stress. Enhancing these pathways can protect neurons from tau-induced toxicity.

ER Stress Modulators

TUDCA (Tauroursodeoxycholic acid): Chemical chaperone that reduces ER stress
Sodium phenylbutyrate: UPR modulator in clinical use
Salubrinal: Selective eIF2α dephosphorylation inhibitor

Protein Disulfide Isomerase (PDI) Modulators

PDI catalyzes disulfide bond formation in proteins. Modulators include:

PDI inhibitors: For acute ER stress
PDI inducers: For chronic proteostasis support

Patient-Specific Considerations

Genetic Variants

MAPT mutations: Specific variants may respond differently to proteostasis modulators
APOE status: APOE4 carriers may have impaired autophagy
GBA variants: Associated with autophagy dysfunction in PSP

NET Assessment

Before initiating proteostasis therapy:

Assess baseline cognitive function (MACE, MoCA)

Evaluate motor symptoms (PSP-RS, CBDRS)

Monitor disease progression rate

Consider CSF biomarkers (total tau, phosphorylated tau)

Drug Interactions

Research Pipeline

Clinical Trials

Emerging Therapies

Gene therapy approaches: AAV-delivered chaperones
Small molecule HSP70 inducers: Preclinical
TFEB agonists: Preclinical
Combination nanotherapy: Experimental

Cross-References

[Tau Aggregation Mechanisms](/mechanisms/tau-aggregation)
[Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome)
[Autophagy in Neurodegeneration](/mechanisms/autophagy-neurodegeneration)
[ER Stress and UPR](/mechanisms/er-stress-upr)

[Corticobasal Syndrome](/diseases/corticobasal-syndrome)
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
[Alzheimer's Disease](/diseases/alzheimers-disease)

References

[Bove J, Martinez-Vicente M, Vila M. Neuroprotection by rapamycin in Parkinson's disease. Autophagy. 2011](https://pubmed.ncbi.nlm.nih.gov/21891913/)

[Sarkar S, Davies JE, Huang Z, et al. Trehalose activates autophagy and reduces pathology in models. J Biol Chem. 2007](https://pubmed.ncbi.nlm.nih.gov/17916779/)

[Doi Y, Nonaka T, Arai N, et al. HDAC6 inhibitor blocks tau aggregate formation. J Neurochem. 2010](https://pubmed.ncbi.nlm.nih.gov/20635454/)

[Rubinsztein DC, Codogno P, Levine B. Autophagy as a disease target. Nat Rev Drug Discov. 2012](https://pubmed.ncbi.nlm.nih.gov/22293458/)

[Settembre C, Di Malta C, Polito VA, et al. TFEB links autophagy to lysosomal biogenesis. Science. 2011](https://pubmed.ncbi.nlm.nih.gov/21546613/)

[Wang M, Kaufman RJ. Protein misfolding in the ER and the unfolded protein response. Nature. 2012](https://pubmed.ncbi.nlm.nih.gov/22418615/)

📖 View canonical wiki page →

Proteostasis Network Enhancement for CBS/PSP

Proteostasis Network Enhancement for CBS/PSP

Overview

Proteostasis Network Enhancement for CBS/PSP

Overview

The Proteostasis Network in CBS/PSP

Therapeutic Strategies

1. Ubiquitin-Proteasome System (UPS) Enhancement

Proteasome Inhibitors

Mechanism

Clinical Considerations

2. Autophagy-Lysosome Pathway Enhancement

Pharmacological Inducers

TFEB Activation

3. Aggresome Targeting

HDAC6 Inhibitors

Mechanism

4. Combination Approaches

5. Heat Shock Protein Modulators

HSP70 Inducers

Mechanism

Clinical Considerations

6. ERAD/UPR Enhancement

ER Stress Modulators

Protein Disulfide Isomerase (PDI) Modulators

Patient-Specific Considerations

Genetic Variants

NET Assessment

Drug Interactions

Research Pipeline

Clinical Trials

Emerging Therapies

Cross-References

Related Mechanisms

Related Diseases

See Also

References